- Home
- RDCM vs RNA Comparison
RDCM vs RNA Comparison
Compare RDCM & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | RNA |
|---|---|---|
| Founded | 1985 | 2025 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 141.3M |
| IPO Year | 1999 | 2025 |
Fundamental Metrics
Financial Performance| Metric | RDCM | RNA |
|---|---|---|
| Price | $10.81 | $7.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $14.00 | ★ $22.00 |
| AVG Volume (30 Days) | 56.5K | ★ 201.5K |
| Earning Date | 11-11-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.07 |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $7.49 |
| 52 Week High | $16.74 | $73.06 |
Technical Indicators
Market Signals| Indicator | RDCM | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 33.80 |
| Support Level | $10.72 | $7.56 |
| Resistance Level | $11.26 | $8.50 |
| Average True Range (ATR) | 0.48 | 0.36 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 57.23 | 6.12 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.